Wellmarker Bio (WMBIO)

Wellmarker Bio (WMBIO) is a biotechnology and pharmaceutical startup that focuses on developing anticancer drugs based on predictive biomarkers with unmet needs. Founded in 2016, the company is a spin-off from the renowned Seoul Asan Medical Center (AMC), the largest hospital in the Republic of Korea. Wellmarker Bio's expertise lies in the development of predictive biomarkers and first-in-class drugs through extensive research know-hows. This is further facilitated by its Research Institute, which comprises the Target discovery department, Drug discovery department, Medicinal chemistry department, and CMC department. The company attracted a significant KRW14.00B Series C investment on 14 October 2021. The investment was led by a consortium of notable investors including Magellan Technology Investment, Seoul Investment Partners, TNC Asset Management, Lead Compass Investment, Elohim Partners, Cytogen, eBEST, Jin & Investment Partners, and GTG Capital Partners, showcasing the trust and interest in Wellmarker Bio's potential. Overall, Wellmarker Bio stands out in the biotechnology and pharmaceutical industries, leveraging its strong ties to a renowned medical center and expertise in predictive biomarkers for the development of innovative anticancer drugs. With a recent substantial Series C investment, the company is well-positioned to advance its research and bring novel treatments to address unmet needs in cancer therapy.